Come and join us across the globe
In his presentation, Laurent Pierot unveiled the one-month results of the COATING trial, the first randomized controlled study comparing a surface-coated flow diverter under single antiplatelet therapy (SAPT) to a bare flow diverter under dual therapy (DAPT). Designed to address the limitations of DAPT, particularly in ruptured aneurysms, this multicenter trial enrolled patients with unruptured or recanalized aneurysms requiring flow diversion. Early data show that the coated device used under SAPT is non-inferior in safety and efficacy, with no increase in thromboembolic or hemorrhagic events. These promising results may pave the way for safer and more flexible antiplatelet strategies in flow diversion. One-year data are still awaited to confirm the long-term benefits.
